Prova Education: Changing the Practice of Medicine

Changing the Practice of Medicine

Discover CME, tools, and guideline-focused education to
improve your knowledge - and patient outcomes.

MinuteCE®
Innovations in Precision Medicine: Leveraging Guideline-Based Immunotherapy and Targeted Treatments in Gynecologic Oncology
1.00 credit 10 episodes
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 credit 10 episodes
Case Applications in Multidisciplinary Care for Endometrial Cancer
Case Applications in Multidisciplinary Care for Endometrial Cancer
MinuteCE®
Case Applications in Multidisciplinary Care for Endometrial Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Evidence- and Guideline-Based Treatment for High-Risk Locally Advanced Cervical Cancer
Evidence- and Guideline-Based Treatment for High-Risk Locally Advanced Cervical Cancer
MinuteCE®
Evidence- and Guideline-Based Treatment for High-Risk Locally Advanced Cervical Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Evidence Base for First-Line Treatment Strategies for Endometrial Cancer and Delivering Guideline-Concordant Care
Evidence Base for First-Line Treatment Strategies for Endometrial Cancer and Delivering Guideline-Concordant Care
MinuteCE®
Evidence Base for First-Line Treatment Strategies for Endometrial Cancer and Delivering Guideline-Concordant Care
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Evidence Base for Treatment Strategies for Endometrial Cancer After Disease Progression and Interdisciplinary Collaboration
Evidence Base for Treatment Strategies for Endometrial Cancer After Disease Progression and Interdisciplinary Collaboration
MinuteCE®
Evidence Base for Treatment Strategies for Endometrial Cancer After Disease Progression and Interdisciplinary Collaboration
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Managing Immune-Related Adverse Events in Cervical and Endometrial Cancer
Managing Immune-Related Adverse Events in Cervical and Endometrial Cancer
MinuteCE®
Managing Immune-Related Adverse Events in Cervical and Endometrial Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
CME/CE
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
0.50 credits
- Neelam Goyal, MD
- Christyn Edmundson, MD
0.50 credits
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and Hematology
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
- Yungan Tao

CME/CE

Screening for Cervical Cancer
Screening for Cervical Cancer
MinuteCE®
Screening for Cervical Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Evidence- and Guideline-Based Treatment for Advanced/Metastatic Cervical Cancer
Evidence- and Guideline-Based Treatment for Advanced/Metastatic Cervical Cancer
MinuteCE®
Evidence- and Guideline-Based Treatment for Advanced/Metastatic Cervical Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Role of Predictive Biomarkers in Endometrial Cancer
Role of Predictive Biomarkers in Endometrial Cancer
MinuteCE®
Role of Predictive Biomarkers in Endometrial Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
MinuteCE®
From Pathway to Patient: Clinical Advances in PI3K-Directed Therapy for HR+/HER2- mBC
0.75 credits 8 episodes
- Komal Jhaveri, MD, FACP
- Kevin Kalinsky MD, MS
0.75 credits 8 episodes
The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
MinuteCE®
The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
0.75 program credits
- Komal Jhaveri, MD, FACP
- Kevin Kalinsky MD, MS
0.75 program credits
Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
MinuteCE®
Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
0.75 program credits
- Komal Jhaveri, MD, FACP
- Kevin Kalinsky MD, MS
0.75 program credits

Clinical Practice

KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Oncology and Hematology
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
- Prof. Markus Hecht
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and Hematology
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
- Yungan Tao
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Oncology and Hematology
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Paul L Swiecicki, MD
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits
MinuteCE®
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  
0.50 credits 3 episodes
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 credits 3 episodes
 Real-World Ready: Practical Tips for Community Oncologists
 Real-World Ready: Practical Tips for Community Oncologists
MinuteCE®
 Real-World Ready: Practical Tips for Community Oncologists
1.00 program credit
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
1.00 program credit

Programs

Applications in Multidisciplinary Care for Cervical Cancer
Applications in Multidisciplinary Care for Cervical Cancer
MinuteCE®
Applications in Multidisciplinary Care for Cervical Cancer
1.00 program credit
- Brian Slomovitz, MD
- Casey Cosgrove, MD
- Michelle Flint, WHNP-BS
1.00 program credit
Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making
Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making
MinuteCE®
Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making
0.75 program credits
- Komal Jhaveri, MD, FACP
- Kevin Kalinsky MD, MS
0.75 program credits
PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
MinuteCE®
PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
0.75 program credits
- Komal Jhaveri, MD, FACP
- Kevin Kalinsky MD, MS
0.75 program credits
Understanding Endocrine Resistance in HR+/HER2- mBC
Understanding Endocrine Resistance in HR+/HER2- mBC
MinuteCE®
Understanding Endocrine Resistance in HR+/HER2- mBC
0.75 program credits
- Kevin Kalinsky MD, MS
0.75 program credits
Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
MinuteCE®
Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
0.75 program credits
- Komal Jhaveri, MD, FACP
- Kevin Kalinsky MD, MS
0.75 program credits
Insights and Updates: New Data on Next-Generation Retinal Treatments
Insights and Updates: New Data on Next-Generation Retinal Treatments
CME/CE
Insights and Updates: New Data on Next-Generation Retinal Treatments
0.50 credits
- Durga Borkar, MD, MMCi
- Veeral Sheth, MD, MBA, FASRS, FACS
0.50 credits

Changing the Practice of Medicine

Popular

CME/CE

Clinical Practice

Programs

Title

Share on ReachMD